Research
Excludes commercial-in-confidence projects.
Targeted inhibition of myeloperoxidase (MPO): A new therapeutic strategy to prevent multiple myeloma progression, Cancer Australia, 25/06/2025 - 30/03/2026
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2024 |
Open access
6
6
|
| 2023 |
26
24
|
| 2023 |
Open access
4
4
|
| 2023 |
Open access
9
8
|
| 2022 |
Open access
5
5
|
| 2021 |
Open access
3
2
|
| 2021 |
Open access
68
60
|
| 2021 |
Open access
4
4
|
| 2021 |
Open access
20
20
|
| 2020 |
Open access
25
25
|
| 2020 |
Open access
10
10
|
| 2020 |
Open access
7
6
|
| 2018 |
Open access
|
| 2017 |
Open access
8
8
|
| 2017 |
17
18
|
| 2017 |
Open access
23
21
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Central Adelaide Local Health Network Incorporated | AUSTRALIA |
| Columbia University Medical Centre | UNITED STATES |
| Flinders University | AUSTRALIA |
| Ku Leuven | BELGIUM |
| Memorial Sloan Kettering Cancer Centre | UNITED STATES |
| Memorial Sloan-Kettering Cancer Center | UNITED STATES |
| Monash University | AUSTRALIA |
| Royal Adelaide Hospital | AUSTRALIA |
| South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
| The Kinghorn Cancer Centre | AUSTRALIA |
| UCB Pharma (United Kingdom) | UNITED KINGDOM |
| University of Adelaide | AUSTRALIA |
| University of Florida | UNITED STATES |
| University of Freiburg | GERMANY |
| University of New South Wales | AUSTRALIA |
| University of South Australia | AUSTRALIA |